PE20160859A1 - Inhibidores de la quinasa reguladora de la senal de apoptosis - Google Patents
Inhibidores de la quinasa reguladora de la senal de apoptosisInfo
- Publication number
- PE20160859A1 PE20160859A1 PE2016000806A PE2016000806A PE20160859A1 PE 20160859 A1 PE20160859 A1 PE 20160859A1 PE 2016000806 A PE2016000806 A PE 2016000806A PE 2016000806 A PE2016000806 A PE 2016000806A PE 20160859 A1 PE20160859 A1 PE 20160859A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- apoptosis signal
- inhibitors
- signal regulatory
- regulatory kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- LCFPCLKTQXMUGV-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]-5-[3-(difluoromethyl)azetidin-1-yl]pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C1)C1=CC(=NC=C1N1CC(C1)C(F)F)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1 LCFPCLKTQXMUGV-UHFFFAOYSA-N 0.000 abstract 1
- UTWWORAHCAYQGO-UHFFFAOYSA-N 5-(3-cyanoazetidin-1-yl)-4-(4-cyclopropylimidazol-1-yl)-N-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)-1,3-thiazol-4-yl]pyridine-2-carboxamide Chemical compound C(#N)C1CN(C1)C=1C(=CC(=NC1)C(=O)NC=1N=C(SC1)C1=NN=CN1C1CC1)N1C=NC(=C1)C1CC1 UTWWORAHCAYQGO-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918784P | 2013-12-20 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160859A1 true PE20160859A1 (es) | 2016-09-18 |
Family
ID=52282961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000806A PE20160859A1 (es) | 2013-12-20 | 2014-12-15 | Inhibidores de la quinasa reguladora de la senal de apoptosis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9169243B2 (OSRAM) |
| EP (1) | EP3083615B1 (OSRAM) |
| JP (3) | JP2016540029A (OSRAM) |
| KR (1) | KR20160098463A (OSRAM) |
| CN (1) | CN105980382A (OSRAM) |
| AP (1) | AP2016009248A0 (OSRAM) |
| AU (1) | AU2014366235B2 (OSRAM) |
| CA (1) | CA2934454C (OSRAM) |
| CL (1) | CL2016001538A1 (OSRAM) |
| CR (1) | CR20160268A (OSRAM) |
| CU (1) | CU20160095A7 (OSRAM) |
| DO (1) | DOP2016000136A (OSRAM) |
| EA (1) | EA201690973A1 (OSRAM) |
| ES (1) | ES2731703T3 (OSRAM) |
| HK (1) | HK1226073A1 (OSRAM) |
| IL (1) | IL245807A0 (OSRAM) |
| MD (1) | MD4658B1 (OSRAM) |
| MX (1) | MX2016008254A (OSRAM) |
| NZ (1) | NZ720660A (OSRAM) |
| PE (1) | PE20160859A1 (OSRAM) |
| PH (1) | PH12016501149A1 (OSRAM) |
| SG (1) | SG11201604473VA (OSRAM) |
| WO (1) | WO2015095059A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| AU2011272782B2 (en) * | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| JP6533799B2 (ja) * | 2014-06-09 | 2019-06-19 | 武田薬品工業株式会社 | 放射標識された化合物 |
| CN110036005B (zh) * | 2016-11-16 | 2022-09-27 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| WO2018094964A1 (zh) * | 2016-11-25 | 2018-05-31 | 武汉大学 | 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法 |
| US20180325931A1 (en) | 2017-01-21 | 2018-11-15 | Ningbo Zhiming Biotechnology Co., Ltd. | Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome |
| PH12019501688B1 (en) * | 2017-01-22 | 2023-08-04 | Fujian Akeylink Biotechnology Co Ltd | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
| WO2018157856A1 (zh) * | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | 酰胺类衍生物抑制剂及其制备方法和应用 |
| ES2971098T3 (es) | 2017-05-12 | 2024-06-03 | Enanta Pharm Inc | Inhibidores de la quinasa 1 que regula la señal de apoptosis y métodos de uso de los mismos |
| US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218051A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019072130A1 (zh) * | 2017-10-12 | 2019-04-18 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| EP3787621B1 (en) * | 2018-05-02 | 2024-12-18 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10683289B2 (en) | 2018-05-02 | 2020-06-16 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CA3104662A1 (en) * | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Ask1 inhibiting agents |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011272782B2 (en) * | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| UY35212A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
-
2014
- 2014-12-15 AU AU2014366235A patent/AU2014366235B2/en not_active Ceased
- 2014-12-15 US US14/570,655 patent/US9169243B2/en active Active
- 2014-12-15 CA CA2934454A patent/CA2934454C/en not_active Expired - Fee Related
- 2014-12-15 MX MX2016008254A patent/MX2016008254A/es unknown
- 2014-12-15 US US15/105,372 patent/US9908875B2/en active Active
- 2014-12-15 EA EA201690973A patent/EA201690973A1/ru unknown
- 2014-12-15 HK HK16114514.0A patent/HK1226073A1/zh unknown
- 2014-12-15 JP JP2016540662A patent/JP2016540029A/ja not_active Withdrawn
- 2014-12-15 KR KR1020167019208A patent/KR20160098463A/ko not_active Withdrawn
- 2014-12-15 CR CR20160268A patent/CR20160268A/es unknown
- 2014-12-15 WO PCT/US2014/070362 patent/WO2015095059A1/en not_active Ceased
- 2014-12-15 EP EP14824288.6A patent/EP3083615B1/en active Active
- 2014-12-15 AP AP2016009248A patent/AP2016009248A0/en unknown
- 2014-12-15 MD MD20160069A patent/MD4658B1/ro not_active IP Right Cessation
- 2014-12-15 ES ES14824288T patent/ES2731703T3/es active Active
- 2014-12-15 CN CN201480069141.7A patent/CN105980382A/zh active Pending
- 2014-12-15 NZ NZ720660A patent/NZ720660A/en not_active IP Right Cessation
- 2014-12-15 SG SG11201604473VA patent/SG11201604473VA/en unknown
- 2014-12-15 PE PE2016000806A patent/PE20160859A1/es not_active Application Discontinuation
-
2016
- 2016-05-24 IL IL245807A patent/IL245807A0/en unknown
- 2016-06-14 PH PH12016501149A patent/PH12016501149A1/en unknown
- 2016-06-14 DO DO2016000136A patent/DOP2016000136A/es unknown
- 2016-06-16 CL CL2016001538A patent/CL2016001538A1/es unknown
- 2016-06-20 CU CUP2016000095A patent/CU20160095A7/es unknown
-
2017
- 2017-08-04 JP JP2017151559A patent/JP6509968B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-29 JP JP2019013185A patent/JP2019077719A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| MX2020000261A (es) | Nuevos compuestos. | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| AR093805A1 (es) | Derivados de piridina agonistas del receptor 2 de cannabinoides | |
| AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
| EA201590548A1 (ru) | Кристаллические формы ингибитора фактора xia | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| BR112015009850A2 (pt) | compostos de piridila substituídos por heteroarila úteis como moduladores de quinase | |
| PE20190653A1 (es) | Nuevos derivados de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| PE20161400A1 (es) | Derivados de isoindolin-1-ona con actividad positiva del modulador alosterico del receptor colinergico muscarinico m1 para el tratamiento de la enfermedad de alzheimer | |
| PE20180227A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| AR089818A1 (es) | Inhibidor de la quinasa que regula la señal de la apoptosis | |
| PH12015500142A1 (en) | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor ror gamma | |
| MX2015011456A (es) | Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. | |
| BR112017013677A2 (pt) | compostos macrocíclicos como inibidores de irak1/4 e usos dos mesmos | |
| EA202091120A3 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| AR064635A1 (es) | Derivados de benzotiazolona | |
| PE20161369A1 (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona | |
| EA201600436A1 (ru) | Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| PE20171443A1 (es) | Derivados de carboxamida | |
| ES2574205T3 (es) | Lactonas esteroideas anticancerosas insaturadas en la posición 7(8) | |
| PE20120402A1 (es) | Piperidinas sustituidas como antagonistas par-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |